Evidence map›Paper›PMID 27942585›Full record

ArticleJCI insight2016

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.

Kan Luo, Hua-Xin Liao, Ruijun Zhang, David Easterhoff, Kevin Wiehe, Thaddeus C Gurley, Lawrence C Armand, Ashley A Allen, Tarra A Von Holle, Dawn J Marshall and 39 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors at 8 institutions in 4 countries.

Kan LuoDuke Human Vaccine Institute.
Hua-Xin LiaoDuke Human Vaccine Institute.
Ruijun ZhangDuke Human Vaccine Institute.
David EasterhoffDuke Human Vaccine Institute.
Kevin WieheDuke Human Vaccine Institute.
Thaddeus C GurleyDuke Human Vaccine Institute.
Lawrence C ArmandDuke Human Vaccine Institute.
Ashley A AllenDuke Human Vaccine Institute.
Tarra A Von HolleDuke Human Vaccine Institute.
Dawn J MarshallDuke Human Vaccine Institute.
John F WhitesidesDuke Human Vaccine Institute.
Jamie PritchettDuke Human Vaccine Institute.
Andrew FoulgerDuke Human Vaccine Institute.
Giovanna HernandezDuke Human Vaccine Institute.
Robert ParksDuke Human Vaccine Institute.
Krissey E LloydDuke Human Vaccine Institute.
Christina StolarchukDuke Human Vaccine Institute.
Sheetal SawantDuke Human Vaccine Institute.
Jessica PeelDuke Human Vaccine Institute.
Nicole L YatesDuke Human Vaccine Institute.
Erika DunfordDuke Human Vaccine Institute.
Sabrina AroraDuke Human Vaccine Institute.
Amy WangDuke Human Vaccine Institute.
Cindy M BowmanDuke Human Vaccine Institute.
Laura L SutherlandDuke Human Vaccine Institute.
Richard M ScearceDuke Human Vaccine Institute.
Shi-Mao XiaDuke Human Vaccine Institute.
Mattia BonsignoriDuke Human Vaccine Institute.
Justin PollaraDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
R Whitney EdwardsDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Sampa SantraCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Norman L LetvinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
James TartagliaSanofi-Pasteur, Swiftwater, Pennsylvania, USA.
Donald FrancisGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Carter LeeGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Jaranit KaewkungwalCenter of Excellence for Biomedical and Public Health Informatics BIOPHICS, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanArmed Forces Research Institute of Medical Sciences-Royal Thai Army Component, Bangkok, Thailand.
Punnee PitisuttithumMahidol University, Bangkok, Thailand.
Supachai Rerks-NgarmDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Nelson L MichaelU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Jerome H KimU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
S Munir AlamDuke Human Vaccine Institute.
Nathan A VandergriftDuke Human Vaccine Institute.
Guido FerrariDuke Human Vaccine Institute.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Georgia D TomarasDuke Human Vaccine Institute.
Barton F HaynesDuke Human Vaccine Institute.
M Anthony MoodyDuke Human Vaccine Institute.
International Vaccine Institute · KRDuke Medical Center · USGlobal Solutions for Infectious Diseases · USBeth Israel Deaconess Medical Center · USMahidol University · THWalter Reed Army Institute of Research · USDepartment of Disease Control · THSanofi (United States) · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
NIAID NIH HHS P30 AI064518NIAID NIH HHS T32 AI007392NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

The ALVAC prime/ALVAC + AIDSVAX B/E boost RV144 vaccine trial induced an estimated 31% efficacy in a low-risk cohort where HIV‑1 exposures were likely at mucosal surfaces. An immune correlates study demonstrated that antibodies targeting the V2 region and in a secondary analysis antibody-dependent cellular cytotoxicity (ADCC), in the presence of low envelope-specific (Env-specific) IgA, correlated with decreased risk of infection. Thus, understanding the B cell repertoires induced by this vaccine in systemic and mucosal compartments are key to understanding the potential protective mechanisms of this vaccine regimen. We immunized rhesus macaques with the ALVAC/AIDSVAX B/E gp120 vaccine regimen given in RV144, and then gave a boost 6 months later, after which the animals were necropsied. We isolated systemic and intestinal vaccine Env-specific memory B cells. Whereas Env-specific B cell clonal lineages were shared between spleen, draining inguinal, anterior pelvic, posterior pelvic, and periaortic lymph nodes, members of Env‑specific B cell clonal lineages were absent in the terminal ileum. Env‑specific antibodies were detectable in rectal fluids, suggesting that IgG antibodies present at mucosal sites were likely systemically produced and transported to intestinal mucosal sites.

Indexed as

Immunity, MucosalAIDS VaccinesAnimalsB-LymphocytesHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsImmunization, SecondaryImmunoglobulin GMacaca mulattaAIDS VaccinesAIDSVAXHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin G

Identifiers

PMID27942585
PMCPMC5135278
OpenAlexW2560657059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.